The present application relates to compositions for use in a method of treating and/or preventing mental and behavioral disorders and/or improving mental health and cognitive functions in a subject comprising: a) Docosahexaenoic acid (DHA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; b) Eicosapentaenoic acid (EPA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; c) gamma-linolenic acid (GLA) and/or the pharmaceutically acceptable deri...

The present application relates to compositions for use in a method of treating and/or preventing mental and behavioral disorders and/or improving mental health and cognitive functions in a subject, comprising: a) Docosahexaenoic acid (DHA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof

The present technology describes a process for preparing inclusion compounds in continuous flow enclosing drugs and cyclodextrins, which is coupled to spray-dryer equipment. This process allows better control of the injection and of the flow of the drug, which is preferably sertraline hydrochloride or sertraline base

PROBLEM TO BE SOLVED: To provide a method for selectively producing (+)-cis-sertraline represented by formula 1 and usable as an intermediate in the production of sertraline hydrochloride.

PURPOSE: A manufacturing method of a (+)-cis-sertaline is provided to manufacture (+)-cis-sertaline of high purity and high yield which does not includes dechlorinated sertaline byproduct, by selectively separating and purifying only a (+)-cis-sertaline. CONSTITUTION: A manufacturing method of a (+-)-cis-sertaline represented by chemical formula 1 comprises: a step of manufacturing (+)-cis-sertaline (S)-(-)-2-pyrrolidone-5-carboxylate by reaction of (+-)-cis/trans-sertaline represented by chemic...

The present application relates to compositions for use in a method of treating and/or preventing mental and behavioral disorders and/or improving mental health and cognitive functions in a subject comprising: a) Docosahexaenoic acid (DHA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; b) Eicosapentaenoic acid (EPA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; c) γ-linolenic acid (GLA) and/or the pharmaceutically acceptable de...

PROBLEM TO BE SOLVED: To provide an antidepressant which achieves high therapeutic effect in a shorter period and can be safely used without any adverse effect. SOLUTION: The pharmaceutical composition for treating/preventing depression includes an earthworm dry powder as an active ingredient. For treating/preventing depression the pharmaceutical composition can be used alone or used in combination with one or more antidepressants selected from the group consisting of clomipramine nortriptyline...

The present invention provides an improved process for preparation of N-[4-(34- dichlorophenyl)-34-dihydro-1-(2H)-naphthalenylidene]methanamine (ketimine) comprising condensation of 4-(34-dichlorophenyl)-34-dihydro-1-(2H)-naphthalenone (sertralone) with monomethyl amine gas in the presence of a dehydrating agent and an aprotic solvent.